Dimensional Fund Advisors’s Rapport Therapeutics RAPP Stock Holding History

Dimensional Fund Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$13.5M	Buy	403,205 +41,091	+11%	+$1.77M	﹤0.01%	2174
2026 Q2	$15.1M	Buy	362,114 +137,616	+61%	+$5.06M	﹤0.01%	2154
2026 Q1	$7.02M	Buy	224,498 +141,011	+169%	+$3.97M	﹤0.01%	2388
2025 Q4	$2.53M	Buy	83,487 +72,157	+637%	+$2M	﹤0.01%	2687
2025 Q3	$337K	Buy	+11,330	New	+$202K	﹤0.01%	3056

Other funds holding RAPP

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Catalyst Private Wealth San Mateo, California $239M AUM 21.76% 1-Year Est. Return

Dimensional Fund Advisors's RAPP Position: Q3 2026 in Review

Dimensional Fund Advisors increased its Rapport Therapeutics (RAPP) stake by 11% in Q3 2026, buying an estimated $1.77M and bringing the position to 403,205 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2174.

Dimensional Fund Advisors first reported a position in RAPP in Q3 2025 and has held it in 5 quarters since. The position peaked at $15.1M in Q2 2026. 41 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

Dimensional Fund Advisors held 403,205 shares of Rapport Therapeutics worth $13.5M as of Q3 2026.
Dimensional Fund Advisors bought 41,091 Rapport Therapeutics shares in Q3 2026, an estimated $1.77M.
Rapport Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #2174 holding.
Dimensional Fund Advisors first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 5 quarters since.
Dimensional Fund Advisors's Rapport Therapeutics position peaked at $15.1M in Q2 2026.
41 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.